100 related articles for article (PubMed ID: 8906133)
21. Topotecan in the treatment of gynecologic cancer.
Coleman RL; Miller DS
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-55-S20-63. PubMed ID: 9425962
[TBL] [Abstract][Full Text] [Related]
22. [Derivatives of camptothecin. A new class of antineoplastic agents].
Astoul C; Ollitrault N; Salvat D
Soins; 1997 Dec; (621):37-40. PubMed ID: 9479219
[No Abstract] [Full Text] [Related]
23. FDA approve bark-derived drug.
Barnett AA
Lancet; 1996 Jun; 347(9015):1613. PubMed ID: 8667876
[No Abstract] [Full Text] [Related]
24. Clinical studies of topotecan.
Broom C
Ann N Y Acad Sci; 1996 Dec; 803():264-71. PubMed ID: 8993520
[No Abstract] [Full Text] [Related]
25. Secondary response of ovarian tumors to topotecan treatment.
Dunton CJ; Neufeld J; Carlson JA
Gynecol Oncol; 1998 Jun; 69(3):258-9. PubMed ID: 9648598
[TBL] [Abstract][Full Text] [Related]
26. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients.
Homesley HD; Hall DJ; Martin DA; Lewandowski GS; Vaccarello L; Nahhas WA; Suggs CL; Penley RG
Gynecol Oncol; 2001 Nov; 83(2):394-9. PubMed ID: 11606103
[TBL] [Abstract][Full Text] [Related]
27. Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan.
Cass I; Kuo DY; Fields AL; Runowicz CD; Goldberg GL
Gynecol Oncol; 1998 May; 69(2):175-8. PubMed ID: 9600828
[No Abstract] [Full Text] [Related]
28. Topotecan in advanced colorectal cancer.
Creemers GJ
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-42-S20-48. PubMed ID: 9425960
[TBL] [Abstract][Full Text] [Related]
29. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
Bookman MA
Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
[TBL] [Abstract][Full Text] [Related]
30. [DNA topoisomerase I inhibitor in the treatment of ovarian neoplasm].
Sun Z; Shen J
Zhonghua Fu Chan Ke Za Zhi; 1999 Jun; 34(6):378-9. PubMed ID: 11360620
[No Abstract] [Full Text] [Related]
31. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K
Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
[TBL] [Abstract][Full Text] [Related]
32. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
33. Topotecan: new preparation. No proven benefit.
Prescrire Int; 1998 Apr; 7(34):48-9. PubMed ID: 10183383
[TBL] [Abstract][Full Text] [Related]
34. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
Lehoczky O; Bagaméri A; Lehoczky G; Pulay T
Orv Hetil; 2002 Apr; 143(16):825-8. PubMed ID: 12053883
[TBL] [Abstract][Full Text] [Related]
35. Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.
Ozols RF
J Clin Oncol; 1997 Jun; 15(6):2177-80. PubMed ID: 9196128
[No Abstract] [Full Text] [Related]
36. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Gordon AN; Tonda M; Sun S; Rackoff W;
Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
[TBL] [Abstract][Full Text] [Related]
37. Topotecan research moves forward at last.
Smart T
GMHC Treat Issues; 1995 Apr; 9(4):1-3. PubMed ID: 11362363
[TBL] [Abstract][Full Text] [Related]
38. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
Markman M; Blessing JA; DeGeest K; Morgan M; Look KY; Herzog TJ; Rose PG
Gynecol Oncol; 1999 Dec; 75(3):444-6. PubMed ID: 10600304
[TBL] [Abstract][Full Text] [Related]
39. [Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer].
Feng F; He X; Shi Y
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):155-8. PubMed ID: 11783024
[TBL] [Abstract][Full Text] [Related]
40. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T
Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
